Literature DB >> 23168412

Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.

Lydia Castro-Núñez1, Esther Bloem, Mariëtte G Boon-Spijker, Carmen van der Zwaan, Maartje van den Biggelaar, Koen Mertens, Alexander B Meijer.   

Abstract

Complex formation between coagulation factor VIII (FVIII) and von Willebrand factor (VWF) is of critical importance to protect FVIII from rapid in vivo clearance and degradation. We have now employed a chemical footprinting approach to identify regions on VWF involved in FVIII binding. To this end, lysine amino acid residues of VWF were chemically modified in the presence of FVIII or activated FVIII, which does not bind VWF. Nano-LC-MS analysis showed that the lysine residues of almost all identified VWF peptides were not differentially modified upon incubation of VWF with FVIII or activated FVIII. However, Lys-773 of peptide Ser-766-Leu-774 was protected from chemical modification in the presence of FVIII. In addition, peptide Ser-764-Arg-782, which comprises the first 19 amino acid residues of mature VWF, showed a differential modification of both Lys-773 and the α-amino group of Ser-764. To verify the role of Lys-773 and the N-terminal Ser-764 in FVIII binding, we employed VWF variants in which either Lys-773 or Ser-764 was replaced with Ala. Surface plasmon resonance analysis and competition studies revealed that VWF(K773A) exhibited reduced binding to FVIII and the FVIII light chain, which harbors the VWF-binding site. In contrast, VWF(S764A) revealed more effective binding to FVIII and the FVIII light chain compared with WT VWF. The results of our study show that the N terminus of VWF is critical for the interaction with FVIII and that Ser-764 and Lys-773 have opposite roles in the binding mechanism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23168412      PMCID: PMC3537036          DOI: 10.1074/jbc.M112.400572

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  The effect of von Willebrand factor on activation of factor VIII by factor Xa.

Authors:  J A Koedam; R J Hamer; N H Beeser-Visser; B N Bouma; J J Sixma
Journal:  Eur J Biochem       Date:  1990-04-30

2.  Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor.

Authors:  Y Takahashi; M Kalafatis; J P Girma; K Sewerin; L O Andersson; D Meyer
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

3.  A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor.

Authors:  P A Foster; C A Fulcher; T Marti; K Titani; T S Zimmerman
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

4.  NMR solution structure of Apis mellifera chymotrypsin/cathepsin G inhibitor-1 (AMCI-1): structural similarity with Ascaris protease inhibitors.

Authors:  T Cierpicki; J Bania; J Otlewski
Journal:  Protein Sci       Date:  2000-05       Impact factor: 6.725

5.  von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain.

Authors:  D C Hill-Eubanks; P Lollar
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

6.  Sequence and structure relationships within von Willebrand factor.

Authors:  Yan-Feng Zhou; Edward T Eng; Jieqing Zhu; Chafen Lu; Thomas Walz; Timothy A Springer
Journal:  Blood       Date:  2012-04-06       Impact factor: 22.113

7.  Association of the factor VIII light chain with von Willebrand factor.

Authors:  P Lollar; D C Hill-Eubanks; C G Parker
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

8.  An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor.

Authors:  P A Foster; C A Fulcher; R A Houghten; T S Zimmerman
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

9.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

Authors:  K M Brinkhous; H Sandberg; J B Garris; C Mattsson; M Palm; T Griggs; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX.

Authors:  K Mertens; A van Wijngaarden; R M Bertina
Journal:  Thromb Haemost       Date:  1985-10-30       Impact factor: 5.249

View more
  5 in total

1.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  Interaction Between the a3 Region of Factor VIII and the TIL'E' Domains of the von Willebrand Factor.

Authors:  Lisbeth Dagil; Kathrin S Troelsen; Gert Bolt; Lars Thim; Bo Wu; Xin Zhao; Edward G D Tuddenham; Thomas E Nielsen; David A Tanner; Johan H Faber; Jens Breinholt; Jakob E Rasmussen; D Flemming Hansen
Journal:  Biophys J       Date:  2019-07-11       Impact factor: 4.033

3.  D' domain region Arg782-Cys799 of von Willebrand factor contributes to factor VIII binding.

Authors:  Małgorzata A Przeradzka; Josse van Galen; Eduard H T M Ebberink; Arie J Hoogendijk; Carmen van der Zwaan; Koen Mertens; Maartje van den Biggelaar; Alexander B Meijer
Journal:  Haematologica       Date:  2019-09-26       Impact factor: 9.941

4.  Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.

Authors:  James R Fuller; Kevin E Knockenhauer; Nina C Leksa; Robert T Peters; Joseph D Batchelor
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

5.  On the versatility of von Willebrand factor.

Authors:  Antoine Rauch; Nikolett Wohner; Olivier D Christophe; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.